← Back to Search

Beta Blocker De-prescription After CABG Surgery for Heart Attack (BEEFBURGER Trial)

Phase 4
Recruiting
Research Sponsored by University of Saskatchewan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18 years treated with index isolated CABG
Be older than 18 years old
Must not have
Peri-CABG stroke
Prior heart failure with reduced ejection fraction (LVEF <45%)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

Summary

This trial found that in patients without reduced heart function or heart failure, beta-blockers did not have a significant impact on cardiovascular risk after CABG surgery.

Who is the study for?
The trial is for adults over 18 who've had coronary artery bypass graft surgery, are on beta blocker therapy at their 6-8 week check-up, and have a heart pumping function of at least 45%. It's not for those with past severe heart failure, recent abnormal heart rhythms or strokes around the time of their surgery.
What is being tested?
This study examines whether patients who've undergone bypass surgery but don't have high-risk features like severe heart failure can safely stop taking beta blockers—a common heart medication—without negative effects on their health.
What are the potential side effects?
While specific side effects aren't listed for stopping beta blockers in this context, generally reducing these medications can potentially lead to increased heart rate, blood pressure changes, and risk of chest pain or even a heart attack if done too quickly.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am over 18 and have had a coronary artery bypass graft.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I had a stroke after heart bypass surgery.
Select...
I have had heart failure with a low heart pumping rate.
Select...
I cannot commit to regular check-ups.
Select...
I have had atrial fibrillation or flutter before or around the time of surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Rate of all-cause mortality
Rate of cardiac arrhythmia
Rate of hospitalizations for heart failure
+4 more
Secondary study objectives
Change in patient reported quality of life (QoL) using Euro Qol (EQ) 5D questionnaire
Change in patient reported quality of life using Short Form (SF) 36 questionnaire
Change in the patient reported angina score using the Seattle Angina Questionnaire (SAQ)

Side effects data

From 2015 Phase 4 trial • 157 Patients • NCT02003391
6%
Ocular hyperaemia
5%
Eye pruritus
2%
Nasopharyngitis
2%
Dry eye
1%
Eye irritation
1%
Blepharal pigmentation
1%
Cataract
1%
Conjunctivitis allergic
1%
Acute tonsillitis
1%
Eyelids pruritus
1%
Pharyngitis
1%
Arthritis
1%
Hypersensitivity
1%
Eye pain
1%
Ocular surface disease
100%
80%
60%
40%
20%
0%
Study treatment Arm
DuoTrav
Beta-blocker

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: De-prescribe beta blocker therapyExperimental Treatment1 Intervention
Beta blocker therapy will be de-prescribed in this arm
Group II: Continue beta blocker therapyActive Control1 Intervention
Participants in this arm will continue their beta blocker therapy as per their usual clinical care

Find a Location

Who is running the clinical trial?

University of SaskatchewanLead Sponsor
253 Previous Clinical Trials
153,960 Total Patients Enrolled
2 Trials studying Myocardial Infarction
260 Patients Enrolled for Myocardial Infarction
Canadian VIGOUR CentreOTHER
8 Previous Clinical Trials
10,848 Total Patients Enrolled
1 Trials studying Myocardial Infarction
60 Patients Enrolled for Myocardial Infarction
Haissam Haddad, MD, FRCPCStudy ChairUniversity of Saskatchewan
1 Previous Clinical Trials
36 Total Patients Enrolled

Media Library

De-prescribe beta blocker therapy Clinical Trial Eligibility Overview. Trial Name: NCT04788186 — Phase 4
Myocardial Infarction Research Study Groups: De-prescribe beta blocker therapy, Continue beta blocker therapy
Myocardial Infarction Clinical Trial 2023: De-prescribe beta blocker therapy Highlights & Side Effects. Trial Name: NCT04788186 — Phase 4
De-prescribe beta blocker therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT04788186 — Phase 4
~50 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top